We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Breakthrough Therapy Designated Oral Drug Could Protect or Reverse COVID-19-Induced Heart Damage

By HospiMedica International staff writers
Posted on 05 Mar 2021
Researchers have discovered some of the ways COVID-19 damages the heart and identified a class of drugs that could potentially protect or reverse this cardiac injury.

A team of researchers from the QIMR Berghofer Medical Research Institute (Queensland, Australia) used thousands of lab-grown, miniature human heart organoids to understand how COVID-19 causes cardiac damage and found that Resverlogix Corp.’s (Calgary, Canada) drug Apabetalone could be a potential treatment for COVID-19-induced heart damage.

Illustration
Illustration

“We exposed the bioengineered, stem-cell-derived heart tissue to COVID-19 patient blood and found it caused dysfunction even when the virus didn’t infect the tissue. These experiments revealed which inflammatory factors are potentially causing the cardiac problems. These factors activate bromodomain protein 4 in the heart, which we found was the key driver of cytokine storm damage,” said Associate Professor James Hudson, head of QIMR Berghofer’s Cardiac Bioengineering Research Group.

“We then used our mini heart organoids to screen several existing drugs that inhibit this protein and found they can prevent and reverse the damage. One of these was apabetalone, which was also effective at blocking the inflammatory response. Because it is already in Phase 3 clinical trials for treating cardiovascular disease, it could be available sooner to treat COVID-19 patients,” added Hudson.

The laboratory tests showed apabetalone also decreased the expression of the receptor protein ACE2, which is found on the cell surface and is used by the SARS-CoV-2 virus to infect cells. Apabetalone belongs to a new class of drugs that has been in clinical trials for cardiovascular disease for more than five years. It has received breakthrough therapy designation from the US Food and Drug Administration. Resverlogix initially planned to study apabetalone to improve clinical status in SARS-CoV-2 infected patients, but will now also examine if it can treat heart damage.

“Not only does apabetalone treatment reduce SARS-CoV-2 infection in cardiomyocytes, but it also prevents cardiac dysfunction induced by cytokine-storm,” said Donald McCaffrey, President and CEO of Resverlogix. “These findings showcase the unique dual-mechanism of apabetalone as a potential treatment for COVID-19 and provide strong support for human clinical trials.”

Related Links:
QIMR Berghofer Medical Research Institute
Resverlogix Corp.



Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Medical Oxygen Analyzer
MAXO2+AE

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles